Shareholder Rights Advocates at Levi & Korsinsky Investigate Cassava …
1 day ago · NEW YORK, NY / ACCESSWIRE / December 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava …
Cassava Sciences and its Alzheimer's drug are done. The damage …
6 days ago · The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s disease, simufilam, failing a clinical trial.
Controversial Alzheimer’s drug from Cassava Sciences fails ... - AAAS
6 days ago · Science reported last year that City University of New York neuroscientist Hoau-Yan Wang—co-discoverer of the experimental compound—was found by a university panel to …
Trial of Controversial Alzheimer’s Drug Halted After Disappointing ...
6 days ago · Cassava Sciences, a small biotechnology company based in Austin, Texas, announced it would stop the advanced clinical trial for an experimental Alzheimer’s drug, …
Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary …
AUSTIN, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on …
PRESS RELEASES - Cassava Sciences, Inc.
Sep 24, 2024 · Company in Advanced Discussions to Resolve SEC Investigation. $40 Million Estimated Loss Contingency Recorded in Q2 for Resolution. Conference Webcast Scheduled …
Cassava Sciences: Probably The End Of The Saga - Seeking Alpha
5 days ago · Cassava Sciences' Phase 3 trial for Alzheimer's failed to meet primary or secondary endpoints, leading to the discontinuation of all ongoing trials. ... transparency and material …
Cassava Sciences’ stock craters after Alzheimer’s disease trial fails ...
Nov 25, 2024 · News is the latest setback for the clinical-stage biotech, which was the subject of SEC and Justice Department investigations earlier this year ... Cassava Sciences Inc.’s stock …
Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary …
Nov 25, 2024 · Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s …
After Cassava Alzheimer drug fiasco, FDA must protect patients
Oct 2, 2024 · For nearly a year, my stance on Cassava Sciences and its Alzheimer’s disease drug candidate simufilam has been clear: Emerging evidence shows the drug is inert, and patients …